Ticker

As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success Given GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in…

Growing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and simplify digital health delivery NEW YORK, Jan. 21, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has surpassed…

CardioGenics (OTCMKTS:CGNH - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Institutional and Insider Ownership 33.4% of DarioHealth shares are owned

First in-market activation of Dario's GenAI roadmap lays clinical and technical foundation for a seamless, conversational AI experience across the entire Dario platform DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further  reinforcing Dario's position as a leader in digital health NEW YORK , Dec.…